LONDON - The prospect of a commercial return from the technology that produced Dolly the cloned sheep was effectively killed last week, when Bayer Healthcare LLC announced it was pulling the plug on the development of alpha-1-antitrypsin (AAT), being developed in a US$40 million collaboration with PPL Therapeutics plc. (BioWorld International)

LONDON - The prospect of a commercial return from the technology that produced Dolly the cloned sheep was effectively killed last week, when Bayer Healthcare LLC announced it was pulling the plug on the development of alpha-1-antitrypsin (AAT), being developed in a US$40 million collaboration with PPL Therapeutics plc. (BioWorld International)

LONDON - The prospect of a commercial return from the technology that produced Dolly the cloned sheep was put on hold Wednesday when Bayer Healthcare announced it was temporarily pulling the plug on the development of alpha-1-antitripsin, being developed in a $40 million collaboration with PPL Therapeutics plc. (BioWorld Today)